CFTR and cystic fibrosis: These findings indicate that clinical outcome measures such as FEV1 % predicted that are commonly used as endpoints in clinical trials have limitations as outcome measure of response to therapy at the level of the CF basic defect, and highlight the importance of including sensitive biomarkers of CFTR function in an approach to personalized medicine of CF.